Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Ionis Pharmaceuticals executive Joseph Baroldi, EVP and Chief Business Officer, reported equity compensation and a stock sale. On January 29, 2026, he acquired 10,278 shares of common stock at $0.0 upon vesting of performance-based restricted stock units, after performance was certified at 167.27% of target shares based on relative total shareholder return.
On January 30, 2026, he sold 5,296 shares of Ionis common stock at a weighted average price of $82.9615 per share, in multiple trades between $82.95 and $82.97. After these transactions, he held 45,413 shares directly, plus 4,772 shares indirectly through his spouse.
A holder of common stock has filed a Form 144 notice to sell 85,089 shares through Stifel Nicolaus & Company on the Nasdaq market. The filing lists an aggregate market value of $7,056,227 for this planned sale, with 161,974,393 shares outstanding for the issuer.
The seller, identified as Frank Bennett, acquired 65,089 shares via an option exercise dated 01/03/2022 and 20,000 shares through restricted stock units dated 01/15/2017. In the past three months, he has already sold 5,885 and 8,977 shares of common stock for gross proceeds of $487,898 and $684,264, respectively.
Ionis Pharmaceuticals had a Form 144 notice filed for the potential sale of 5,296 shares of its common stock through Morgan Stanley Smith Barney on or about 01/30/2026. The filing lists an aggregate market value of $439,693.50 for these shares on Nasdaq.
The shares to be sold were acquired on 01/29/2026 as performance stock units granted under the company’s 2011 Equity Incentive Plan as compensation. The notice states that 161,974,393 shares of common stock were outstanding and discloses a prior sale of 6,907 shares for $523,205.25 on 01/16/2026.
A holder of Ionis Pharmaceuticals common stock filed a notice of proposed sale of 6,179 shares under Rule 144. These shares have an aggregate market value of 512,271.93 and will be sold through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 01/30/2026.
The securities were acquired as performance stock units granted under Ionis’ 2011 Equity Incentive Plan on 01/29/2026, with compensation as the form of payment. The notice also discloses a prior sale of 8,480 common shares on 01/16/2026 for gross proceeds of 636,932.80, and states that 161,137,930 common shares were outstanding.
Ionis Pharmaceuticals reported a planned sale of 5,885 shares of its common stock under Rule 144. The shares, with an aggregate market value of $487,897.77, are expected to be sold on or about January 30, 2026 through Morgan Stanley Smith Barney on NASDAQ.
The seller acquired these 5,885 shares on January 29, 2026 via performance stock units granted under the company’s 2011 Equity Incentive Plan as compensation. During the prior three months, 8,977 Ionis common shares were also sold, generating gross proceeds of $674,621.55.
A shareholder of Ionis Pharmaceuticals has filed a notice to sell 6,988 shares of common stock through Morgan Stanley Smith Barney on 01/30/2026 on NASDAQ. The filing lists an aggregate market value of $580,049.03 for this planned sale.
The shares were acquired on 01/29/2026 as performance stock units granted under the company’s 2011 Equity Incentive Plan and treated as compensation. Over the prior three months, the same account sold 12,922 common shares for $971,992.84.
Ionis Pharmaceuticals insider plans additional stock sale under Rule 144. A person associated with Ionis plans to sell 62,970 shares of common stock through broker Morgan Stanley Smith Barney on or about 01/30/2026 on NASDAQ, with an aggregate market value of 5,223,748.59.
The shares come from performance stock units granted under the company’s 2011 Equity Incentive Plan and delivered as compensation on 01/29/2026. During the prior three months, the same broker sold 44,034 shares of Ionis common stock for gross proceeds of 3,294,623.88 for the same account.
Ionis Pharmaceuticals insider plans a Rule 144 stock sale. A holder intends to sell 6,179 shares of Ionis common stock through Morgan Stanley Smith Barney on or about 01/30/2026 on NASDAQ, with an aggregate market value of $512,905.75.
The shares were acquired on 01/29/2026 as performance stock units granted under Ionis’ 2011 Equity Incentive Plan and paid as compensation. The filer also reports a prior sale in the last three months of 9,191 common shares for gross proceeds of $697,045.44.
Ionis Pharmaceuticals has a Form 144 notice covering the planned sale of 6,179 shares of its common stock through Morgan Stanley Smith Barney on NASDAQ. The aggregate market value of these shares is $512,905.75.
The shares were acquired on 01/29/2026 as performance stock units (PSUs) granted under the company’s 2011 Equity Incentive Plan as compensation. Ionis had 161,137,930 common shares outstanding. During the prior three months, the same broker sold 23,463 and 9,884 Ionis shares, for gross proceeds of $1,856,324.51 and $744,660.56.
Ionis Pharmaceuticals has a planned sale of 6,179 shares of its common stock through Morgan Stanley Smith Barney on NASDAQ, with an approximate sale date of 01/30/2026 and an aggregate market value of 512,905.75. These shares were acquired on 01/29/2026 as performance stock units granted under the company’s 2011 Equity Incentive Plan and paid as compensation.
The notice also reports that 9,302 common shares of Ionis were sold on 01/16/2026, generating gross proceeds of 703,138.18. The form includes a representation that the seller is not aware of any undisclosed material adverse information about Ionis’ current or prospective operations.